BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28640458)

  • 1. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
    Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
    Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
    BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
    Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
    Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
    Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
    Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
    Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
    Yamanashi K; Chen-Yoshikawa TF; Hamaji M; Yurugi K; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Date H
    Gen Thorac Cardiovasc Surg; 2020 Feb; 68(2):142-149. PubMed ID: 31435872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation.
    Cihan Y; Kanzelmeyer N; Drube J; Kreuzer M; Lerch C; Hennies I; Froede K; Verboom M; Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2017 Nov; 32(11):2133-2142. PubMed ID: 28717935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year.
    Lerut E; Naesens M; Kuypers DR; Vanrenterghem Y; Van Damme B
    Transplantation; 2007 Jun; 83(11):1416-22. PubMed ID: 17565313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
    Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
    J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
    Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.